Previous 10 | Next 10 |
Cincinnati-based Meridian Bioscience (NASDAQ: VIVO) would seem to be an unlikely player in the global coronavirus fight. This week, however, the company announced that one of its reagents is being used in the development of molecular diagnostics for that virus. Because the reagen...
Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP ) +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...
In response to the new coronavirus, pharmaceutical companies across the market have begun to step up work on tests and treatments amid the growing unease about the disease’s spread. One such firm, Utah-based Co-Diagnostics (NASDAQ: CODX ) has completed the first phase of design for a ...
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started o...
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical tes...
CINCINNATI, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020 financial results Friday, February 7, 2020. Jack Kenny, Chief Executive Officer, and Bryan Bal...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q4 2019 Earnings Call Nov 7, 2019 , 10:00 a.m. ET Operator Continue reading
Meridian Bioscience, Inc. (VIVO) Q4 2019 Earnings Conference Call November 7, 2019 10:00 AM ET Company Participants Bryan Baldasare – Chief Financial Officer Jack Kenny – Chief Executive Officer Conference Call Participants Bill Quirk – Piper Jaffray B...
Meridian Bioscience (NASDAQ: VIVO ): Q3 Non-GAAP EPS of $0.13 beats by $0.04 ; GAAP EPS of $0.10 beats by $0.02 . Revenue of $50.8M (-4.3% Y/Y) beats by $0.23M . Shares -3% PM. Press Release More news on: Meridian Bioscience, Inc., Earnings news and commentary, Healthcare stoc...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...